References
1 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108. DOI:10.3322/caac.21262.
2 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30. DOI:10.3322/caac.21442.
3 Darai E, Rouzier R, Ballester M, Barranger E, Coutant C. Sentinel lymph node biopsy in gynaecological cancers: the importance of micrometastases in cervical cancer. SURG ONCOL. 2008;17:227-35. DOI:10.1016/j.suronc.2008.04.002.
4 Niikura H, Okamoto S, Otsuki T, Yoshinaga K, Utsunomiya H, Nagase S, et al. Prospective Study of Sentinel Lymph Node Biopsy Without Further Pelvic Lymphadenectomy in Patients With Sentinel Lymph Node-Negative Cervical Cancer. INT J GYNECOL CANCER. 2012;22:1244-50. DOI:10.1097/IGC.0b013e318263f06a.
5 Cabanas RM. An approach for the treatment of penile carcinoma. CANCER-AM CANCER SOC. 1977;39:456-66.
6 Tax C, Rovers MM, de Graaf C, Zusterzeel PL, Bekkers RL. The sentinel node procedure in early-stage cervical cancer, taking the next step; a diagnostic review. GYNECOL ONCOL. 2015;139:559-67. DOI:10.1016/j.ygyno.2015.09.076.
7 NCCN Cervical cancer guidelines. Version II.2018; Available from. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf; NCCN.org. (2018.11.10).
8 Chambers LM, Vargas R, Michener CM. Sentinel lymph node mapping in endometrial and cervical cancer: a survey of practices and attitudes in gynecologic oncologists. J GYNECOL ONCOL. 2019;30. DOI:10.3802/jgo.2019.30.e35.
9 Abu-Rustum NR, Khoury-Collado F, Gemignani ML. Techniques of sentinel lymph node identification for early-stage cervical and uterine cancer. GYNECOL ONCOL. 2008;111: S44-S50. DOI:https://doi.org/10.1016/j.ygyno.2008.07.027.
10 Di Guilmi J, Darin MC, Toscano M, Maya G. Laparoscopic Sentinel Lymph Node Mapping with Indocyanine Green Using the iSpies Platform: Initial Experience Argentina. J MINIM INVAS GYN. 2018;25:378-9. DOI:https://doi.org/10.1016/j.jmig.2017.09.004.
11 Bricou A, Barranger E, Uzan S, Darai E. Anaphylactic shock during the sentinel lymph node procedure for cervical cancer. GYNECOL ONCOL. 2009;114:375-6. DOI:https://doi.org/10.1016/j.ygyno.2009.04.027.
12 Sun SP, Zhang Y, Cui ZQ, Chen Q, Zhang W, Zhou CX, et al. Clinical application of carbon nanoparticle lymph node tracer in the VI region lymph node dissection of differentiated thyroid cancer. GENET MOL RES. 2014;13:3432-7. DOI:10.4238/2014.April.30.4.
13 Khoury-Collado F, Glaser GE, Zivanovic O, Sonoda Y, Levine DA, Chi DS, et al. Improving sentinel lymph node detection rates in endometrial cancer: How many cases are needed? GYNECOL ONCOL. 2009;115:453-5. DOI:https://doi.org/10.1016/j.ygyno.2009.08.026.
14 Cibula D, Zikan M, Slama J, Fischerova D, Kocian R, Germanova A, et al. Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer. GYNECOL ONCOL. 2016;143:83-6. DOI:10.1016/j.ygyno.2016.07.101.
15 Tanaka T, Sasaki S, Tsuchihashi H, Terai Y, Yamamoto K, Yamada T, et al. Which is better for predicting pelvic lymph node metastases in patients with cervical cancer: Fluorodeoxyglucose-positron emission tomography/computed tomography or a sentinel node biopsy? A retrospective observational study. Medicine (Baltimore). 2018;97:e0410. DOI:10.1097/md.0000000000010410.
16 Dundr P, Cibula D, Nemejcova K, Ticha I, Bartu M, Jaksa R. Pathologic Protocols for Sentinel Lymph Nodes Ultrastaging in Cervical Cancer. Arch Pathol Lab Med. 2019. doi:10.5858/arpa.2019-0249-RA.
17 Yahata H, Kobayashi H, Sonoda K, Kodama K, Yagi H, Yasunaga M, et al. Prognostic outcome and complications of sentinel lymph node navigation surgery for early-stage cervical cancer. INT J CLIN ONCOL. 2018;23:1167-72. DOI:10.1007/s10147-018-1327-y.
18 Lennox GK, Covens A. Can sentinel lymph node biopsy replace pelvic lymphadenectomy for early cervical cancer? GYNECOL ONCOL. 2017;144:16-20. DOI:10.1016/j.ygyno.2016.08.337.
19 Yang SX, Wei WS, Jiang QH, Zhou YF, Qu W, Tu JH, et al. Analysis of 246 sentinel lymph node biopsies of patients with clinical primary breast cancer by application of carbon nanoparticle suspension. J Obstet Gynaecol Res. 2018;44:1150-7. DOI:10.1111/jog.13635.
20 Li Z, Ao S, Bu Z, Wu A, Wu X, Shan F, et al. Clinical study of harvesting lymph nodes with carbon nanoparticle suspension in advanced gastric cancer: a prospective randomized trial. World J Surg Oncol. 2016;14:88.
21 Zhao WJ, Luo H, Zhou YM, Gou ZH, Wang B, Zhu JQ. Preoperative ultrasound-guided carbon nanoparticle suspension localization for metastatic lymph nodes in papillary thyroid carcinoma during reoperation: a retrospective cohort study. Medicine (Baltimore). 2017;96:e6285.
22 Lu Y, Wei JY, Yao DS, Pan ZM, Yao Y. Application of carbon nanoparticles in laparoscopic sentinel lymph node detection in patients with early-stage cervical cancer. PLOS ONE. 2017;12:e0183834. DOI:10.1371/journal.pone.0183834.
23 Altgassen C, Hertel H, Brandstaedt A, Koehler C, Duerst M, Schneider A. Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO study group. J CLIN ONCOL. 2008;26:2943-51. DOI:10.1200/jco.2007.13.8933.
24 Rocha A, Maria Dominguez A, Lecuru F, Bourdel N. Indocyanine green and infrared fluorescence in detection of sentinel lymph nodes in endometrial and cervical cancer staging - a systematic review. Eur J Obstet Gynecol Reprod Biol. 2016;206:213-9. DOI:10.1016/j.ejogrb.2016.09.027
25 Di Guilmi J, Darin MC, Toscano M, Maya G. Laparoscopic Sentinel Lymph Node Mapping with Indocyanine Green Using the iSpies Platform: Initial Experience Argentina. J MINIM INVAS GYN. 2018;25:378-9. DOI:https://doi.org/10.1016/j.jmig.2017.09.004.
26 Barthelmes L, Goyal A, Newcombe RG, McNeill F, Mansel RE. Adverse reactions to patent blue V dye - The NEW START and ALMANAC experience. Eur J Surg Oncol. 2010;36:399-403. DOI:10.1016/j.ejso.2009.10.007.
27 Zakaria S, Hoskin TL, Degnim AC. Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. AM J SURG. 2008;196:228-33. DOI:10.1016/j.amjsurg.2007.08.060.
28 Ouldamer L, Marret H, Acker O, Barillot I, Body G. Unusual localizations of sentinel lymph nodes in early-stage cervical cancer: A review. Surg Oncol. 2012;21: E153-E7. DOI:10.1016/j.suronc.2012.04.003.
29 Lukas R, Helena R, Jiri HM, Martin H, Petr S. Current status of sentinel lymph node mapping in the management of cervical cancer. Expert Rev Anticancer Ther. 2013;13:861-70. DOI:10.1586/14737140.2013.811147.
30 Daraï E, Rouzier R, Ballester M, Barranger E, Coutant C. Sentinel lymph node biopsy in gynaecological cancers: The importance of micrometastases in cervical cancer. Surgical Oncology. 2008;17:227-35. DOI:https://doi.org/10.1016/j.suronc.2008.04.002.
31 Cibula, D., Oonk, M. H. & Abu-Rustum, N. R. Sentinel lymph node biopsy in the management of gynecologic cancer. ”Curr Opin Obstet Gynecol,2.411” 27, 66-72, doi:10.1097/gco.0000000000000133 (2015).
32 Cibula D, Abu-Rustum NR, Dusek L, et al. Bilateral ultrastaging of sentinel lymph node in cervical cancer: lowering the false-negative rate and improving the detection of micrometastasis. Gynecol Oncol. 2012;127(3):462–466.
33 Slama J, Dundr P, Dusek L, Cibula D. High false negative rate of frozen section examination of sentinel lymph nodes in patients with cervical cancer. GYNECOL ONCOL. 2013;129:384-8. DOI:10.1016/j.ygyno.2013.02.001.
34 Kim JH, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. The efficacy of sentinel lymph node mapping with indocyanine green in cervical cancer. WORLD J SURG ONCOL. 2018;16:52. DOI:10.1186/s12957-018-1341-6.
35 O’Boyle JD, Coleman RL, Bernstein SG, Lifshitz S, Muller CY, Miller DS. Intraoperative lymphatic mapping in cervix cancer patients undergoing radical hysterectomy: A pilot study. GYNECOL ONCOL. 2000;79:238-43. DOI:10.1006/gyno.2000.5930.
36 Moncayo VM, Alazraki AL, Alazraki NP, Aarsvold JN. Sentinel Lymph Node Biopsy Procedures. Semin Nucl Med. 2017;47:595-617. DOI:https://doi.org/10.1053/j.semnuclmed.2017.06.004.
37 Eiriksson, L. R. & Covens, A. Sentinel lymph node mapping in cervical cancer: the future? ”Bjog-An International Journal Of Obstetrics And Gynaecology,5.193” 119, 129-133, doi:10.1111/j.1471-0528.2011.03134.x (2012).
38 Twu NF, Ou YC, Liao CI, Chang WY, Yang LY, Tang YH, et al. Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. SURG ONCOL. 2016;25:229-35. DOI:10.1016/j.suronc.2016.05.028.
39 Colturato, L. F., Signorini Filho, R. C., Fernandes, R. C., et al. Lymph node micrometastases in initial stage cervical cancer and tumoral recurrence. Int J Gynaecol Obstet 133, 69-75, doi:10.1016/j.ijgo.2015.08.019 (2016).
40 Chandacham A, Charoenkwan K, Siriaunkgul S. et al. Extent of lymphovascular space invasion and risk of pelvic lymph node metastases in stage IB1 cervical cancer. J Med Assoc Thai 88 Suppl 2, S31-36 (2005).
41 Yanaranop M, Sathapornteera N, Nakrangsee S. Risk factors of pelvic lymph node metastasis in cervical adenocarcinoma following radical hysterectomy and pelvic lymphadenectomy. J Med Assoc Thai. 2014;97 Suppl 11: S87-95.
Table 1. Thepatients’ demographic and clinicopathologic informationand analysis of impact factors on the SLNB detection rate
Categorical variables are presented as absolute frequency (N) and relative frequency (%), continuous variables are presented as mean(min-max), comparison between detection rates indicate significance at P <0.05, “a”:P-value of continuous correction chi-square test, SLN: sentinel lymph node, SLNB: sentinel lymph node biopsy, LVSI: lymphovascular space invasion.